04:51 , Nov 3, 2017 |  BC Week In Review  |  Company News

Abzena, UGA Biopharma develop biosimilar cell line

Antibody company Abzena plc (LSE:ABZA) and biosimilar manufacturer UGA Biopharma GmbH (Hennigsdorf, Germany) said they developed a murine myeloma manufacturing cell line expressing a biosimilar to treat multiple sclerosis. The partners developed and validated the...
16:08 , Aug 11, 2017 |  BC Week In Review  |  Company News

Abzena grants Telix rights to PSMA antibodies

Abzena plc (LSE:ABZA) granted Telix Pharmaceuticals Ltd. (North Melbourne, Australia) exclusive, worldwide rights to develop and commercialize therapeutics and diagnostics based on preclinical prostate-specific membrane antigen (PSMA; FOLH1; GCPII) antibodies. The companies said Telix plans...
18:46 , Jul 21, 2017 |  BC Week In Review  |  Company News

OBI gains ThioBridge linker tech from Abzena for OBI-999 and other ADCs

Abzena plc (LSE:ABZA) granted OBI Pharma Inc. (TPEx:4174) exclusive, worldwide rights to ThioBridge antibody drug conjugate (ADC) linker- technology which OBI will use to develop its preclinical cancer candidate OBI-999 and other undisclosed ADCs to...
23:11 , Feb 24, 2017 |  BioCentury  |  Product Development

Dendritic cell control

Denceptor Therapeutics Ltd. is developing a technology for inducing antigen-specific T cell responses that the company believes will be more efficacious than other dendritic cell-targeted approaches for cancer while avoiding the safety issues raised by...
20:36 , Jan 6, 2017 |  BC Week In Review  |  Company News

Abzena, Trieza deal

Abzena granted Trieza exclusive, worldwide rights to an undisclosed antibody sequence for use in combination with Trieza's viral vector technology to develop cancer treatments. The sequence was created using Abzena’s Composite Human Antibody technology. Abzena...
20:23 , Dec 9, 2016 |  BC Week In Review  |  Clinical News

GS-5745: Development discontinued

Gilead discontinued development of subcutaneous GS-5745 to treat CD and UC. The company said GS-5745 showed "no evidence of benefit" in a double-blind, placebo-controlled, international Phase II trial in patients with moderate to severe CD....
19:58 , Dec 6, 2016 |  BC Week In Review  |  Clinical News

Simtuzumab: Development discontinued

Gilead said it discontinued development of subcutaneous simtuzumab for all indications after data from 3 double-blind, placebo-controlled, international Phase IIb trials showed a lack of efficacy. The trials evaluated simtuzumab to treat PSC; to treat...
07:00 , Jul 25, 2016 |  BC Week In Review  |  Company News

Abzena, Baylor Scott & White Research Institute deal

Abzena and the institute formed JV Denceptor Therapeutics Ltd. to develop immunotherapies against cancer and autoimmune diseases using the institute’s dendritic cell receptor-targeting antibodies, which Abzena will humanize using its Composite Human Antibody technology. Denceptor...
08:00 , Feb 8, 2016 |  BC Week In Review  |  Company News

Abzena deal

Abzena granted an undisclosed U.S. cancer company non-exclusive rights to use Abzena’s ThioBridge antibody drug conjugate (ADC) linker technology for up to three targets. Abzena will receive a license fee and target nomination fee and...
08:00 , Dec 7, 2015 |  BC Week In Review  |  Financial News

Abzena proposes placing

Abzena plc (LSE:ABZA), Babraham, U.K.   Business: Supply/Service, Antibodies   Date announced: 2015-11-24   Type: Placing   To be raised: Up to L21 million ($31.8 million)   Shares: 35 million   Price: 60p   Shares outstanding prior: 97.5 million   Placement agents: Cenkos...